CardiovascularORALGeneric
MYCOSTATIN
NYSTATIN
Standard Dose
200,000 UNITS
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview MYCOSTATIN is listed in Drugs@FDA under application 050619 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient NYSTATIN Form and strength PASTILLE;ORAL - 200,000 UNITS Sponsor DELCOR ASSET CORP Submission history Latest submission status date: 2003-04-30 00:00:00.
Structured Monograph
Clinical summary
Approval overview MYCOSTATIN is listed in Drugs@FDA under application 050619 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NYSTATIN Form and strength PASTILLE;ORAL - 200,000 UNITS Sponsor DELCOR ASSET CORP Submission history Latest submission status date: 2003-04-30 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.